Literature DB >> 9633710

Cognitive screening examinations for silent cerebral infarcts in sickle cell disease.

M R DeBaun1, J Schatz, M J Siegel, M Koby, S Craft, L Resar, J Y Chu, G Launius, M Dadash-Zadeh, R B Lee, M Noetzel.   

Abstract

OBJECTIVE: In children with sickle cell disease (SCD), silent cerebral infarcts are the most frequent cause of neurologic injury. We determined the sensitivity and specificity of selective neurocognitive measures when separating children with silent cerebral infarcts and SCD from sibling controls. Additionally, we tested the validity of the same cognitive measures to identify patients with overt strokes.
METHODS: We examined performance on a neuropsychologic battery containing measures of attention/executive, spatial, language, memory, and motor functioning for seven children with SCD and silent cerebral infarct, 21 children with SCD and overt stroke, and 17 normal siblings. Diagnosis of cerebral infarct was based on results of MRI.
RESULTS: Measures from the attention and executive domains were the most useful for identifying children with silent cerebral infarct. The Test of Variables of Attention was the most robust measure and yielded a sensitivity rate of 86% and a specificity rate of 81%. This measure also showed a sensitivity rate of 95% in identifying overt stroke.
CONCLUSIONS: Brief cognitive screening measures, if properly constructed, may be an effective means of identifying children with silent cerebral infarct. Future prospective studies should be pursued to assess the utility of cognitive screening for silent cerebral infarcts in SCD.

Entities:  

Mesh:

Year:  1998        PMID: 9633710     DOI: 10.1212/wnl.50.6.1678

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  32 in total

1.  Cognitive functioning in children from Nigeria with sickle cell anemia.

Authors:  Olubusola B Oluwole; Robert B Noll; Daniel G Winger; Olu Akinyanju; Enrico M Novelli
Journal:  Pediatr Blood Cancer       Date:  2016-07-09       Impact factor: 3.167

Review 2.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 3.  Pathophysiology of Sickle Cell Disease.

Authors:  Prithu Sundd; Mark T Gladwin; Enrico M Novelli
Journal:  Annu Rev Pathol       Date:  2018-10-17       Impact factor: 23.472

Review 4.  Neuropsychological aspects of pediatric sickle cell disease.

Authors:  M C Kral; R T Brown; G W Hynd
Journal:  Neuropsychol Rev       Date:  2001-12       Impact factor: 7.444

5.  Ameliorating attention problems in children with sickle cell disease: a pilot study of methylphenidate.

Authors:  Brian Daly; Mary C Kral; Ronald T Brown; David Elkin; Avi Madan-Swain; Monica Mitchell; Lori Crosby; David Dematteo; Angela Larosa; Sherron Jackson
Journal:  J Dev Behav Pediatr       Date:  2012-04       Impact factor: 2.225

6.  Cognitive and behavior deficits in sickle cell mice are associated with profound neuropathologic changes in hippocampus and cerebellum.

Authors:  Li Wang; Luis E F Almeida; Celia M de Souza Batista; Alfia Khaibullina; Nuo Xu; Sarah Albani; Kira A Guth; Ji Sung Seo; Martha Quezado; Zenaide M N Quezado
Journal:  Neurobiol Dis       Date:  2015-10-14       Impact factor: 5.996

Review 7.  Targeting pain at its source in sickle cell disease.

Authors:  Kanika Gupta; Om Jahagirdar; Kalpna Gupta
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2018-03-28       Impact factor: 3.619

Review 8.  Sickle cell disease in Africa: burden and research priorities.

Authors:  J Makani; T N Williams; K Marsh
Journal:  Ann Trop Med Parasitol       Date:  2007-01

9.  Working Memory in Children With Neurocognitive Effects From Sickle Cell Disease: Contributions of the Central Executive and Processing Speed.

Authors:  Kelsey E Smith; Jeffrey Schatz
Journal:  Dev Neuropsychol       Date:  2016-10-19       Impact factor: 2.253

10.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.